DR REDDYS LABORATORIES LTD (RDY) Stock
RDY has an Alpha Score of 33 out of 100 (poor), computed on Nov 5, 2026 from 3 of 4 sub-scores. 5 of the hedge funds AlphaScala tracks reported RDY in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Renaissance Technologies's at $106.46M. Its trailing P/E ratio is 40.8 and its net margin 8.5% (key statistics as of Nov 5, 2026).
What is RDY's Alpha Score?
How it works →Alpha Score of 33 reflects weak overall profile with moderate momentum, poor value, weak quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 5, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own RDY?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Renaissance Technologies Jim Simons (founder) | 7.35M | $106.46M | -7% |
| Marshall Wace | 2.03M | $29.35M | -24% |
| Millennium Management Israel Englander | 468K | $6.79M | +721% |
| D.E. Shaw David Shaw | 127K | $1.83M | -9% |
| Citadel Ken Griffin | 79K | $1.15M | -82% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are RDY's key statistics?
Key statistics as of Nov 5, 2026
How does RDY's valuation compare with the Healthcare sector?
| Metric | RDY | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 40.8 | 28.8 | 113 |
| Net margin | 8.46% | 3.66% | 170 |
| Return on equity | 2.99% | 3.71% | 194 |
| Dividend yield (payers) | 0.71% | 1.59% | 55 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 9, 2026). P/E excludes loss-making companies.
RDY price chart
Powered by TradingViewWhat does DR REDDYS LABORATORIES LTD do?
Dr. Reddy's Laboratories Ltd. is a prominent pharmaceutical company, engaged in the research, development, manufacturing, and marketing of a wide array of generic medicines, active pharmaceutical ingredients (APIs), and biosimilars. Founded in 1984, the company plays a critical role in providing affordable healthcare solutions on a global scale. Dr. Reddy's Laboratories is known for its robust product portfolio that extends across various therapeutic areas, including oncology, gastroenterology, cardiovascular, and dermatology. The company's global footprint spans both emerging markets and developed economies, allowing it to serve diverse patient populations and adhere to different regulatory landscapes. In the financial markets, Dr. Reddy's Laboratories is significant due to its contribution to the healthcare sector, providing alternatives to high-priced medications and promoting access to essential drugs. As part of its commitment to addressing health challenges, the company invests heavily in research and innovation to meet the evolving needs of patients worldwide. Dr. Reddy's not only impacts the pharmaceutical industry but also contributes to the broader life sciences market with its focus on sustainability and compliance with international quality standards.